Please assess the completion status of the following clinical trial:

Trial Title: Symptom Burden in Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with a pathologically proven diagnosis of epithelial carcinoma of the oropharynx, nasopharynx, hypopharynx, larynx, or oral cavity being treated at MDACC.~2. Patients \>/= 18 years old and \</= 65 years old.~3. Patients with the above cancers scheduled to receive definitive concurrent chemoradiation over 6 - 7 weeks.~4. Patients who speak English (due to the novel research and its complexity, we are only accruing English speaking patients to the protocol)~5. Patients must agree to discontinue any current herbal supplement use, and refrain from taking any herbal supplement while on protocol.~6. Patients must be willing and able to review, understand, and provide written consent.~7. Women of childbearing potential (women who are not postmenopausal for at least one year and are not surgically sterile) must have negative urine pregnancy test..~8. Sexually active males and females must agree to use birth control or abstinence for the duration of the trial.~Exclusion Criteria:~1. Patients who are taking medications or have conditions that potentially preclude use of any study medications or interventions as determined by the treating physician~2. Patients taking CHANTIX (smoking cessation medication)~3. Patients who are enrolled in other symptom management trial or receiving active therapy as part of a treatment clinical trial.~4. Bile duct obstruction or cholelithiasis~5. History of clinically significant cutaneous drug reaction, or a history of clinically significant hypersensitivity reaction, including multiple allergies or drug reaction~6. Pre-existing psychosis or bipolar disorder. Patients with major depressive disorder or severe depression (a score of 13 or greater on the BDI Fast Screen (BDI-FS) will be excluded. If this is the case, we will notify their treating physician for appropriate management or referral.~7. Pre-existing renal impairment: The screening cut off for serum creatinine \> the upper limit of normal, will be done by the oncologist to qualify for chemoradiation.~8. Pre-existing hepatic impairment: The screening for total bilirubin \> 1.5 times the upper limit of normal will be done by the oncologist to qualify for chemoradiation. The screening for \>2 times the upper limit of normal hepatotoxicity: Alkaline phosphatase (ALP) and Alanine aminotransferase (ALT) will be done by the oncologist to qualify for chemoradiation.The screening results for Aspartate aminotransferase (AST) must be \< 2 times the upper limit of normal if available in the medical records.~9. Pre-existing Tourette's syndrome~10. Seizure disorder~11. Anorexia/bulimia in past two months~12. Use of monoamine oxidase (MAO inhibitors) within 14 days~13. Patients undergoing abrupt discontinuation of ethanol or sedatives (including benzodiazepines)~14. Patients currently taking any of the study drugs~15. Hypersensitivity to any tetracyclines~16. Patients on anticoagulants (ie warfarin/heparin)~17. Patients with INR \> 1.5.~18. Patients being treated with concurrent cetuximab chemotherapy with radiation therapy.~19. Patients currently receiving any tetracycline family antibiotic or within the previous past 14 days before chemoradiation.~20. Previous radiation therapy for a cancer in the head and neck region.~21. Patients with a history of cardiac disease, including angina and cardiac ischemia, left ventricular hypertrophy, myocardial infarction, and mitral valve prolapse.~22. Patients taking antifungals, antiretrovirals, and macrolides that are strong CYP3A4 strong inhibitors including indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, and nefazodone.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo by mouth 2 times every day.
- Armodafinil (Type: EXPERIMENTAL): Armodafinil 150 mg by mouth once a day.
- Minocycline (Type: EXPERIMENTAL): Minocycline 100 mg by muth two times a day.
- Bupropion (Type: EXPERIMENTAL): Bupropion 100 mg by mouth two times a day.
- Armodafinil + Minocycline (Type: EXPERIMENTAL): Armodafinil 150 mg by mouth once a day.~Minocycline 100 mg by mouth two times a day.
- Armodafinil + Bupropion (Type: EXPERIMENTAL): Armodafinil 150 mg by mouth once a day.~Bupropion 100 mg by mouth two times a day.
- Minocycline + Bupropion (Type: EXPERIMENTAL): Minocycline 100 mg by muth two times a day.~Bupropion 100 mg by mouth two times a day.
- Armodafinil + Minocycline + Bupropion (Type: EXPERIMENTAL): Armodafinil 150 mg by mouth once a day.~Minocycline 100 mg by muth two times a day.~Bupropion 100 mg by mouth two times a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues